Browse > Article

Verification with of High Efficiency Chemical Binding System of a Physiologically Active Radioisotope Using ESI-TOF/Ms System  

Joh, Eun-Ha (Radioisotope Research Division, Department of Research Reactor Utilization, Korea Atomic Energy Research Institute (KAERI))
Hong, Young Don (Radioisotope Research Division, Department of Research Reactor Utilization, Korea Atomic Energy Research Institute (KAERI))
Choi, Sun Ju (Radioisotope Research Division, Department of Research Reactor Utilization, Korea Atomic Energy Research Institute (KAERI))
Publication Information
YAKHAK HOEJI / v.57, no.6, 2013 , pp. 400-405 More about this Journal
Abstract
In this study, we measured the complex efficiency of a physiologically active antibody, a chelator and radiosiotopes using the ESI-TOF/Ms system for develop good radiopharmaceuticals. For a precise measurement, TLC is a low accuracy method. Loading of same amount of sample is difficult for each test, and work to quantify accurately the results obtained through TLC cannot be afforded compared to the use of other analytical instruments. The method of analysis using a mass spectrometer is capable of a mass analysis of proteins for quantitative analysis. The conjugates of the chelator (CHX-A- DTPA) and the antibody (IgG) were separated through MWCO, and were analyzed using ESI-TOF and MALDI-TOF mass spectrometry. The analysis using MALDI-TOF is roughly divided into measurements on mass spectrometry. When conjugating a small molecular weight of CHX-A-DTPA and a large molecular weight of IgG, distinguishing the peak of the conjugate and the peak of IgG was difficult. However, an ESI-TOF mass spectrometer system is capable of an analysis of mass by decentralizing the IgG. It is utilized as a technique for measuring the metabolic processes during conjugation and the stability evaluation of radiopharmaceuticals. When establishing this technique, the accuracy of the overall radiophar-maceutical analysis is expected to be able to be improved.
Keywords
$^{177}Lu$; CHX-A-DTPA; radioisotope; massspectrometer; immunoglobulin G;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Rainer, M., Sajdik, C. and Bonn, G. K. : Mass spectrometric profiling of low-molecular-weight proteins. Methods. Mol. Biol. 1023, 83 (2013).   DOI   ScienceOn
2 Wu, S. Y., Kuo, J. W., Chang, T. K., Liu, R. S., Lee, R. C., Wang, S. J., Lin, W. J. and Wang, H. E. : Preclinical characterization of 18F-MAA, a novel PET surrogate of 99mTc-MAA. Nucl. Med. Biol. 39, 1026 (2012).   DOI   ScienceOn
3 Günel, S. E. and Akgun, A. : Comparison of exercise-restreinjection Tl-201 imaging and rest sublingual isosorbide dinitrate Tc-99m MIBI imaging for the assessment of myocardial viability. Ann. Nucl. Med. 23, 451 (2009).   DOI
4 Narayanan, M. V., King, M. A. and Byrne, C. L. : An iterative transmission algorithm incorporating cross-talk correction for SPECT. Med. Phys. 29, 694 (2002).   DOI   ScienceOn
5 Abbasi, I. A. : Preliminary studies on (177)Lu-labeled sodium pyrophosphate (177Lu-PYP) as a potential bone-seeking radiopharmaceutical for bone pain palliation. Nucl. Med. Biol. 39, 763 (2012).   DOI   ScienceOn
6 Brans, B., Mottaghy, F. M. and Kessels, A. : 90Y/177Lu- DOTATATE therapy: survival of the fittest? Eur. J. Nucl. Med. Mol. Imaging. 38, 1785 (2011).   DOI
7 Seidl, C. and Essler, M. : Radioimmunotherapy for peritoneal cancers. Immunotherapy 5, 395 (2013).   DOI   ScienceOn
8 Ozkan, E., Aras, G. and Kucuk, N. O. : Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I wholebody scan results. Clin. Nucl. Med. 38, 326 (2013).   DOI
9 Chakravarty, R., Dash, A. and Pillai, M. R. : Availability of yttrium-90 from strontium-90: a nuclear medicine perspective. Cancer. Biother. Radiopharm. 27, 621 (2012).   DOI   ScienceOn
10 Snyder, E. H., O'Connor, G. A. and McAvoy, D. C. : Fate of 14C-triclocarban in biosolids-amended soils. Sci. Total. Environ. 408, 2726 (2010).   DOI   ScienceOn
11 Wiwanitkit, V. : 177Lu-nimotuzumab. Nucl. Med. Biol. 39, 891 (2012).   DOI   ScienceOn